Vaxart (NASDAQ:VXRT) Share Price Crosses Above Fifty Day Moving Average of $0.76

Vaxart, Inc. (NASDAQ:VXRT)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.76 and traded as high as $0.85. Vaxart shares last traded at $0.83, with a volume of 544,600 shares changing hands.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald cut their target price on shares of Vaxart from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, August 7th.

Vaxart Trading Up 1.0 %

The company has a market capitalization of $126.32 million, a price-to-earnings ratio of -1.09 and a beta of 0.64. The firm’s 50 day simple moving average is $0.76 and its 200-day simple moving average is $0.85.

Vaxart (NASDAQ:VXRT) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $1.36 million during the quarter, compared to analyst estimates of $0.10 million. As a group, sell-side analysts forecast that Vaxart, Inc. will post -0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Vaxart

Institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP acquired a new position in Vaxart in the 3rd quarter valued at $34,000. Bank of Montreal Can acquired a new position in shares of Vaxart during the 2nd quarter worth $67,000. BNP Paribas Arbitrage SA grew its stake in shares of Vaxart by 165.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 25,643 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 15,974 shares during the period. Centiva Capital LP acquired a new position in shares of Vaxart during the 4th quarter worth $37,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Vaxart during the 2nd quarter worth $29,000. 19.04% of the stock is owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.